PDF(Pubmed)
Abstract：
Aim: Assess the time-to-treatment discontinuation (TTD) and overall survival (OS) in a Swedish metastatic renal cell carcinoma (mRCC) nationwide cohort who received second-line axitinib.Methods: Retrospective analysis of 110 patients with mRCC treated with second-line axitinib in Sweden (2012-2019). Patients included in the study received axitinib after mainly first-line sunitinib or pazopanib.Results: The median (95% CI) TTD of patients who received second-line axitinib was 5.2 (3.7-6.1) months with 6 (5.5%) patients still receiving treatment at the time of analysis. Median (95% CI) OS was 12.2 (7.7-14.2) months.Conclusion: The results are consistent with previous findings in mRCC and add to the evidence demonstrating efficacy of second-line axitinib, after failure of a prior anti-angiogenic therapy in a real-world setting.Clinical Trial Registration: NCT04669366 (ClinicalTrials.gov).
[Box: see text].
[Box: see text].
摘要：
目的：评估接受二线阿西替尼的瑞典转移性肾细胞癌（mRCC）全国队列中的停药时间（TTD）和总生存期（OS）。方法:回顾性分析2012-2019年瑞典110例接受二线阿西替尼治疗的mRCC患者。纳入研究的患者主要在一线舒尼替尼或帕唑帕尼之后接受阿西替尼治疗。结果：接受二线阿昔替尼治疗的患者的TTD中位数（95％CI）为5.2（3.7-6.1）个月，其中6名（5.5％）患者在分析时仍在接受治疗。中位（95%CI）OS为12.2（7.7-14.2）个月。结论：该结果与mRCC的先前发现一致，并增加了证明二线阿西替尼疗效的证据，在现实世界中先前的抗血管生成治疗失败后。临床试验注册：NCT04669366（ClinicalTrials.gov）。
[方框：见正文]。
[方框：见正文]。
